Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry
Summary
MINNEAPOLIS & IRVINE, Calif.--( BUSINESS WIRE )--Be The Match BioTherapies, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the worlds leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry.The collaboration will support both organizations’ efforts to standardize critical elements of the cell therapy supply chain, as well as processes in apheresis and transplant center networks.“We are delighted to partner with Cryoport to support the growing cell and gene therapy industry,” said Chris McClain, MBA, vice president, Sales and New Business Development, Be The Match BioTherapies.We are pleased to join them in these industry-leading efforts and look forward to working together to support cell and gene therapy companies to more efficiently bring new medicines to patients,” said Mark Sawicki, chief commercial officer of Cryoport.Backed by the industry-leading experience of the National Marrow Donor Program/Be The Match , and a research partnership with the ® ), the organization designs solutions that advance cell and gene therapies in any stage of development.